AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update
PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and LMI.
- PI-2620 was discovered and developed using the Morphomer® platform as part of a research collaboration between AC Immune and LMI.
- Snow previously held the title of Associate Vice President, Financial Reporting and prior to joining AC Immune worked as a manager at BDO.
- G&A Expenditures: G&A expenses decreased by CHF 2.1 million for the year ended December 31, 2022 to CHF 15.8 million.
- AC Immune anticipates that its total cash burn will be in the range of CHF 65 to CHF 75 million for the full year 2023.